Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Pfizer to Supply COVID-19 Vaccine Doses for 60 Million People in Japan
Pfizer and German partner BioNTech have agreed to provide Japan with a supply of 120 million doses of their coronavirus vaccine for 60 million people by the end of June next year, Health Minister Katsunobu Kato said on July 31.…
To read the full story
Related Article
- Japan Cancels Purchase of 40 Million AstraZeneca Shots: Official
April 12, 2022
- Health Minister Hails Domestic Production Plan for AstraZeneca Vaccine
February 8, 2021
- AstraZeneca Files COVID-19 Vaccine in Japan
February 5, 2021
- Japan, Pfizer Finalize COVID-19 Vaccine Deal, Agree on Supply of 144 Million Doses
January 21, 2021
- Decision on Pfizer Vaccine Unlikely to Come before Japan Data Submission Slated by February
December 21, 2020
- Pfizer/BioNTech’s COVID-19 Vaccine Filed in Japan, Exceptional OK Eyed
December 18, 2020
- AstraZeneca, Japan Govt Ink Definitive Deal on COVID-19 Vaccine
December 11, 2020
- Pfizer, BioNTech Begin Japan PI/II Study for COVID-19 Vaccine
October 21, 2020
- Japan to Earmark 671.4 Billion Yen to Secure Coronavirus Vaccines, Anticipating Final Agreements with 3 Companies
September 9, 2020
- AstraZeneca to Supply 120 Million Doses of COVID-19 Vaccine to Japan
August 11, 2020
REGULATORY
- Celltrion’s Eylea Biosimilar Nears Approval, but Listing Outlook Clouded
February 27, 2026
- Japan Panel to Review Joenja, Dojolvi for Approval at March 5 Session
February 27, 2026
- Japan to Closely Monitor US “MFN” Policy: PM Takaichi
February 27, 2026
- Japan to Update Adult Pneumococcal Fact Sheet Ahead of Capvaxive NIP Review
February 27, 2026
- Takaichi Signals Continued Off-Year Revisions despite Abolition Calls
February 26, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…